US Dollar vs MXN

Regístrate para interactuar en nuestros foros activos para discutir con inversores de ideas afines.

Regístrate

SXTP 60 Degrees Pharmaceuticals Inc

0.42985

0.18385 (74.74%)

Última actualización: 11:14:12

Retrasado por 15 minutos

Form EFFECT - Notice of Effectiveness

60 Degrees Pharmaceuticals (NASDAQ:SXTP)
Gráfica de Acción Histórica
De Jun 2024 a Jul 2024

Haga Click aquí para más Gráficas 60 Degrees Pharmaceuticals.

60 Degrees Pharmaceuticals (NASDAQ:SXTP)
Gráfica de Acción Histórica
De Jul 2023 a Jul 2024

Haga Click aquí para más Gráficas 60 Degrees Pharmaceuticals.

Noticias sobre 60 Degrees Pharmaceuticals Inc SXTP

60 Degrees Pharmaceuticals Signs Clinical Trial Agreements With All Planned Trial Sites for Tafenoquine Babesiosis Study
Viernes 19 de Julio 2024 (4 horas hace) • GlobeNewswire Inc.

Form EFFECT - Notice of Effectiveness
Jueves 18 de Julio 2024 (12 horas hace) • Edgar (US Regulatory)

Form 8-K - Current report
Martes 16 de Julio 2024 (3 días hace) • Edgar (US Regulatory)

Form S-3 - Registration statement under Securities Act of 1933
Viernes 12 de Julio 2024 (7 días hace) • Edgar (US Regulatory)

Form 8-K - Current report
Martes 9 de Julio 2024 (1 semana hace) • Edgar (US Regulatory)

60 Degrees Pharma Announces IRB Approval of Clinical Study of Tafenoquine for Treatment of Babesiosis in Immunocompromised Patients with Persistent Babesia microti Despite Prior Treatment
Martes 9 de Julio 2024 (1 semana hace) • GlobeNewswire Inc.

First Patient Enrolled in 60 Degrees Pharmaceuticals Clinical Trial of Tafenoquine for Babesiosis at Tufts Medical Center; First and Only Study of Its Kind
Jueves 27 de Junio 2024 (3 semanas hace) • GlobeNewswire Inc.

60 Degrees Pharmaceuticals Receives FDA Orphan Drug Designation for Tafenoquine for Treatment of Patients with Acute Babesiosis
Martes 11 de Junio 2024 (1 mes hace) • GlobeNewswire Inc.

Enrollment in 60 Degrees Pharmaceuticals Clinical Trial of Tafenoquine for Babesiosis to Begin at Tufts Medical Center; First Study of Its Kind
Jueves 30 de Mayo 2024 (2 meses hace) • GlobeNewswire Inc.

60 Degrees Pharmaceuticals Funds Babesia spp Testing in Chronic Fatigue Patient Samples in NC State College of Veterinary Medicine Study
Lunes 20 de Mayo 2024 (2 meses hace) • GlobeNewswire Inc.

60 Degrees Pharmaceuticals Announces First Quarter 2024 Results
Miércoles 15 de Mayo 2024 (2 meses hace) • GlobeNewswire Inc.

60 Degrees Pharmaceuticals Outlines Upcoming Clinical Trial of Tafenoquine in Babesiosis in Letter to Journal of Infectious Diseases
Miércoles 8 de Mayo 2024 (2 meses hace) • GlobeNewswire Inc.

Más de 60 Degrees Pharmaceuticals Inc Artículos de Noticias

Bnp Paribas Issuance

BNP Paribas Issuance

Vontobel Financial Produ...

Intesa Sanpaolo

NLBNPIT1V9K6 20991231 64...

NLBNPIT21HD8 20240918 38...

Xtrackers MSCI EM Europe...

iShares Global Timber & ...

Vontobel Financial Produ...

Delayed Upgrade Clock

Soporte: (55) 4170 8128 | soporte@advfn.mx

Al acceder a los servicios disponibles de ADVFN usted acepta quedar sujerto a los Términos y Condiciones